NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, essential to energy metabolism and DNA repair, and is a major focus of ageing-biology research because cellular NAD+ levels are known to decline with age. It is sold for laboratory research use only.
What is NAD+?
NAD+ is not a peptide in the strict sense — it's a dinucleotide coenzyme — but it's grouped alongside research peptides commercially because of how it's supplied and used in laboratory settings. It exists in every cell in the body and cycles between an oxidised form (NAD+) and a reduced form (NADH), acting as an electron carrier in the metabolic reactions that generate cellular energy. It's also a required substrate for several enzyme families, including sirtuins and PARPs, both of which are central to current ageing-biology research.
The proposed mechanism
The research interest in NAD+ stems from a well-established observation: NAD+ levels measurably decline in many tissues as organisms age, across species studied so far. Because NAD+ is a substrate that sirtuins and PARPs require to function, and because both enzyme families are implicated in DNA repair and metabolic regulation, researchers have proposed that restoring or maintaining NAD+ levels might influence the cellular processes these enzymes govern. This is one of the more mechanistically well-characterised areas of the "longevity" peptide/coenzyme literature.
What the published research shows
The NAD+ literature is extensive and includes:
- Biochemical studies establishing NAD+'s role in glycolysis, the citric acid cycle, and oxidative phosphorylation.
- Sirtuin research, examining how NAD+ availability affects sirtuin enzyme activity in cell and animal models.
- Ageing-biology studies measuring NAD+ decline across tissues and age groups, and studying NAD+ precursor supplementation (NMN, NR) in animal models for its effects on metabolic markers.
- DNA-damage response research, given NAD+'s role as a PARP substrate in repair pathways.
It's worth distinguishing between NAD+ itself, its precursors (NMN and NR, which are more commonly used in oral human studies), and the direct NAD+ research material sold for laboratory use — a distinction the popular press covering "NAD+ supplements" often blurs. Direct NAD+ administration research (as opposed to precursor studies) is a smaller, more specialised body of literature, largely conducted in cell and animal models.
Research status and open questions
The mechanistic case for NAD+'s role in ageing biology is stronger than for many research compounds, precisely because the coenzyme's biochemistry has been studied since the early 20th century. What remains genuinely open is whether raising NAD+ levels in an intact organism produces the downstream effects predicted from cell-culture sirtuin studies, and how that translates across tissue types — an active area of ongoing animal research.
UK regulatory status
NAD+ sold as a research chemical carries no UK marketing authorisation for any therapeutic use and is supplied strictly for laboratory research, distinct from NAD+ precursor products sold as food supplements under different regulatory categories.
Sourcing research-grade NAD+ in the UK
NAD+ is chemically less stable than many peptides and is sensitive to freeze-thaw cycling and light exposure, so storage guidance and batch date matter more here than for some other research materials. Flex Peptides lists NAD+ with COA data available on request and UK-based dispatch.
Study Design Considerations for NAD+ Research
Researchers designing NAD+-related laboratory work typically need to account for the coenzyme's instability more than they would for a standard peptide. NAD+ degrades relatively quickly once reconstituted or exposed to repeated freeze-thaw cycles, and several published methodology papers specifically address measurement technique — HPLC and enzymatic cycling assays are the two most common ways NAD+/NADH ratios are quantified in a research setting, and each has different sensitivity and interference profiles that matter when comparing results across studies. Researchers should also be careful to distinguish between studies measuring intracellular NAD+ levels directly and those inferring NAD+ status indirectly from downstream sirtuin or PARP activity, since these are not interchangeable measures and the literature sometimes conflates them.
A further practical point for anyone reviewing this literature: because NAD+ precursor research (NMN, NR) has attracted substantially more recent funding and publication volume than direct NAD+ administration studies, search results and review articles can be skewed toward precursor findings even when the topic is nominally "NAD+ research" — worth checking which specific molecule a given paper actually tested before drawing conclusions relevant to direct NAD+ work.
Key takeaways
- NAD+ is a coenzyme, not a peptide, but is supplied and used similarly in laboratory research.
- It is required for sirtuin and PARP enzyme activity, both central to ageing-biology research.
- NAD+ levels are well-documented to decline with age across studied tissues and species.
- Direct NAD+ research is distinct from the more common NMN/NR precursor literature.
- Storage stability is a bigger practical factor for NAD+ than for many other research peptides.
FAQ
**Is NAD+ the same as NMN or NR? **
No — NMN and NR are precursor molecules the body converts into NAD+; NAD+ itself is the end coenzyme, and each has a distinct research literature.
Why does NAD+ get grouped with peptide research?
Commercially, it's sold and stored under similar research-chemical conditions, and much of the surrounding research overlaps with cellular-ageing and metabolic peptide research more broadly.
How should NAD+ be stored between experiments?
Following the supplier's specific storage guidance is important given its instability — typically frozen, protected from light, and used within a limited window after reconstitution to preserve measurable activity.Are NAD+ precursor studies relevant to research using NAD+ directly?
They're related but not interchangeable — precursor studies measure the pharmacokinetics of NMN or NR conversion to NAD+, while direct NAD+ studies bypass that conversion step, and the two literatures should be read as distinct.
For laboratory research use only. Not for human consumption.
